🐦 推特Wall St EngineCodex · 实盘不做把握 4/10
北京时间·🕒 发布 18:15:31时区推断·⟳ 抓取 18:16:20·⚡ 决策 07-29 18:18:05 +1m45s·90.3 天前
Biogen二季度收入和调整后EPS超预期，但社媒摘要中的全年EPS指引口径存在冲突
二季度收入27亿美元、调整后EPS 3.60美元均高于市场预期，成长组合收入同比增长24%，说明新产品组合继续接棒传统MS业务。
📄 原文Wall St Engine@wallstengine↗ 原文
BIOGEN $BIIB Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $2.7B (Est. $2.46B) 🟢; +3% YoY 🔹 Adj. EPS: $3.60 (Est. $2.95) 🟢; -34%…
不做 Biogen（BIIB.US）
财报摘要方向混合且EPS指引口径冲突；排期内财报前股价已放量上涨，做多edge不清晰，做空也不满足强空催化和借券核验。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司提前公告二季度财报将在2026-07-29美股盘前发布，事件属于排期内财报。
- 社媒快速转发二季度财报摘要，给出收入和EPS超预期以及成长组合增长，但全年EPS指引口径疑似混用。市场反应:美股当时仍处盘前未开盘，连续交易不可成交。
- 财经媒体报道Biogen二季度收入和调整后EPS超预期，并称公司上调全年调整后EPS指引，与社媒摘要中的EPS下调口径不一致。
- 财报前一交易日Biogen收涨2.73%至205.61美元、成交量高于50日均量，说明财报前已有一定押注。市场反应:BIIB 2026-07-28收盘205.61美元，+2.73%。
关键理由
- 二季度收入27亿美元、调整后EPS 3.60美元均高于市场预期，成长组合收入同比增长24%，说明新产品组合继续接棒传统MS业务。
- 但该信号把全年EPS指引写成12-13美元且低于前值，而公开财经报道显示Biogen上调的是全年调整后EPS指引，GAAP/Non-GAAP口径冲突会直接改变方向判断。
- 财报日披露本身是排期事件，Biogen前一交易日已上涨2.73%且成交量高于均值，追财报正向 surprise 的边际不清晰。
主要风险
- 若后续官方材料确认实际是调整后EPS上修且盘前承接强，当前不做可能错过正向重定价；需由新的确认信号接手。
- 若市场聚焦GAAP指引下调或并购摊销压力，股价可能继续承压，但当前净利空不够干净且未核到Futu可借券，不能开空。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-29 · 影响 weakens
公开财经报道显示调整后EPS指引为上调，而社媒摘要写的是reported EPS下调，关键口径冲突削弱做多。
检索:Biogen Q2 2026 earnings EPS guidance cut adjusted EPS raised 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-07-29 · 影响 weakens
收入、调整后EPS和成长组合均好于预期，且非GAAP指引可能上调，不支持把该事件当作干净强空催化。
检索:Biogen Q2 2026 revenue EPS beat growth portfolio revenue guidance raised 原文 ↗
原文全文
展开原文 · 1,205 字
BIOGEN $BIIB Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $2.7B (Est. $2.46B) 🟢; +3% YoY
🔹 Adj. EPS: $3.60 (Est. $2.95) 🟢; -34% YoY
🔹 Growth Portfolio Revenue: $1.06B; +24% YoY
FY26 Guide:
🔹 EPS (Reported): $12-$13 (Est. $12.7) 🟡
🔹 Prior Reported EPS Guide: $14.25-$15.25
🔹 Total Revenue: Mid-single-digit % increase
🔹 H2 R&D+SG&A Expense: $2.65B-$2.70B
Segment Net Revenue:
🔹 SPINRAZA: $402M; +2% YoY
🔹 VUMERITY: $197M; -7% YoY
🔹 LEQEMBI: $184M; +15% YoY
🔹 SKYCLARYS: $168M; +29% YoY
🔹 SYFOVRE: $162M; +8% YoY
🔹 ZURZUVAE: $71M; +53% YoY
🔹 EMPAVELI: $46M; +123% YoY
🔹 Legacy MS Portfolio: $767M
Comments:
🔸 “This quarter is a reflection of the significant progress Biogen has made repositioning the company for long-term growth. Not only did our growth portfolio revenue exceed that of our legacy MS portfolio, delivering 24% of year-over-year growth, we also delivered strong revenue performance from our two recently acquired products, providing an opportunity for our pipeline to build on a growing business.”
🔸 “At the same time, our scientific leadership continues to translate into commercial momentum, with a successful launch of SPINRAZA HD and historic approval of LEQEMBI IQLIK at-home initiation.”
🔹 Revenue: $2.7B (Est. $2.46B) 🟢; +3% YoY
🔹 Adj. EPS: $3.60 (Est. $2.95) 🟢; -34% YoY
🔹 Growth Portfolio Revenue: $1.06B; +24% YoY
FY26 Guide:
🔹 EPS (Reported): $12-$13 (Est. $12.7) 🟡
🔹 Prior Reported EPS Guide: $14.25-$15.25
🔹 Total Revenue: Mid-single-digit % increase
🔹 H2 R&D+SG&A Expense: $2.65B-$2.70B
Segment Net Revenue:
🔹 SPINRAZA: $402M; +2% YoY
🔹 VUMERITY: $197M; -7% YoY
🔹 LEQEMBI: $184M; +15% YoY
🔹 SKYCLARYS: $168M; +29% YoY
🔹 SYFOVRE: $162M; +8% YoY
🔹 ZURZUVAE: $71M; +53% YoY
🔹 EMPAVELI: $46M; +123% YoY
🔹 Legacy MS Portfolio: $767M
Comments:
🔸 “This quarter is a reflection of the significant progress Biogen has made repositioning the company for long-term growth. Not only did our growth portfolio revenue exceed that of our legacy MS portfolio, delivering 24% of year-over-year growth, we also delivered strong revenue performance from our two recently acquired products, providing an opportunity for our pipeline to build on a growing business.”
🔸 “At the same time, our scientific leadership continues to translate into commercial momentum, with a successful launch of SPINRAZA HD and historic approval of LEQEMBI IQLIK at-home initiation.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。